LiliumX uses a unique protein technology platform to facilitate scalable discovery of first-in-class bispecific biologics. We can work with antibody fragments and other proteins - even natural ligands. We explore unprecedented mechanisms of action to push the boundaries of bispecific antibodies.
By physically linking two distinct targets, bispecific antibodies can treat cancer in unique ways. But bispecific antibody discovery is either scalable or flexible - Not both. LiliumX breaks free of this restriction.
LiliumX is building an unprecedented pipeline for internal and collaborative discovery of bispecific antibodies, from protein design through robotic screening and AI analysis.
Reach out to learn more.